Can Patients on Long-Term Rosuvastatin Develop Myalgia After Recent Shingles?
Yes, patients on long-term rosuvastatin can develop myalgia after a recent shingles outbreak, but the myalgia is most likely directly caused by the rosuvastatin itself rather than the shingles infection. However, the clinical picture is complicated by the fact that statins may increase the risk of herpes zoster infection in the first place.
Understanding the Relationship
Rosuvastatin-Induced Myalgia is Common
Myalgia is a well-established adverse effect of rosuvastatin that can occur at any time during therapy, not just at initiation. According to FDA labeling data, myalgia occurs in 2.8% of patients overall on rosuvastatin (vs 1.3% on placebo), with rates as high as 6.3% in patients on 20mg and 12.7% in longer-term studies 111. Importantly, muscle symptoms can appear at any point during statin therapy, even after years of stable use 2.
The Statin-Shingles Connection
Emerging evidence suggests a bidirectional relationship:
Statins increase herpes zoster risk: Population-based studies demonstrate that statin therapy increases the risk of herpes zoster infection by 13-21% 34. In an Asian cohort of 53,069 patients, statin users had a 21% higher risk of HZ infection (HR 1.21,95% CI 1.13-1.29) 3. A Canadian study of nearly 500,000 elderly patients confirmed this association (HR 1.13,95% CI 1.10-1.17) 4.
The mechanism: Statins have immunomodulatory properties that may favor reactivation of latent varicella-zoster virus 4.
Clinical Approach When Myalgia Develops
When a patient on long-term rosuvastatin develops myalgia coinciding with or following shingles, you must systematically evaluate for statin-induced myopathy:
Obtain creatine kinase (CK) immediately and compare to baseline if available 2
Check thyroid-stimulating hormone (TSH) - hypothyroidism predisposes to myopathy and must be ruled out 2
Assess for other risk factors that increase myopathy risk 2:
- Advanced age (especially >80 years)
- Small body frame/frailty
- Renal insufficiency
- Drug interactions (especially with CYP2C9 or transporter inhibitors)
- Recent perioperative period
Rule out common non-statin causes of myalgia such as exercise or strenuous activity 2
Management Strategy
If statin-induced myopathy is suspected (even with normal CK), discontinue rosuvastatin temporarily 52. The Canadian guidelines emphasize that most patients with statin intolerance can be successfully rechallenged - 92% of patients who were rechallenged remained on a statin at 12 months 5.
After symptom resolution and CK normalization:
- Rechallenge with a different statin (62-81% may tolerate an alternative) 5
- Consider lower or intermittent dosing of rosuvastatin (weekly 5-10mg can achieve >10% LDL reduction with improved tolerability) 5
- Consider non-statin alternatives if rechallenge fails 5
Critical Pitfalls to Avoid
- Do not assume myalgia is solely from shingles/post-herpetic neuralgia without evaluating for statin myopathy - the timing may be coincidental
- Do not continue the statin if CK is >10x ULN with symptoms - this risks progression to rhabdomyolysis 2
- Do not dismiss normal CK levels - statin-associated muscle symptoms can occur without CK elevation 5
- Consider immune-mediated necrotizing myopathy if symptoms persist after statin discontinuation - check anti-HMG-CoA reductase antibodies 6
The Diagnostic Dilemma
A recent case report illustrates the complexity: a 69-year-old on high-dose atorvastatin presented with myalgias and vesicular rash initially thought to be herpes zoster, but ultimately had statin-induced autoimmune necrotizing myopathy with CK >9000 U/L and positive anti-HMG-CoA reductase antibodies 6. This underscores that the clinical presentation can be confounded when both conditions coexist.
Bottom line: When myalgia develops in a patient on rosuvastatin with recent shingles, systematically evaluate for statin myopathy with CK and TSH, and maintain a low threshold for temporary statin discontinuation to clarify the etiology.